` ADAG (Adagene Inc) vs S&P 500 Comparison - Alpha Spread

ADAG
vs
S&P 500

Over the past 12 months, ADAG has underperformed S&P 500, delivering a return of -3% compared to the S&P 500's +14% growth.

Stocks Performance
ADAG vs S&P 500

Loading
ADAG
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ADAG vs S&P 500

Performance Gap Between ADAG and GSPC
HIDDEN
Show

Performance By Year
ADAG vs S&P 500

Loading
ADAG
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Adagene Inc vs Peers

S&P 500
ADAG
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Adagene Inc
Glance View

Market Cap
88.6m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
HIDDEN
Show
Back to Top